EUVIMEDEUVIMED entdecken
Open Access

Nonlobular Invasive Breast Carcinomas with Biallelic Pathogenic CDH1 Somatic Alterations: A Histologic, Immunophenotypic, and Genomic Characterization

Fatemeh Derakhshan, Arnaud Da Cruz Paula, Pier Selenica, Edaise M da Silva, Anne Grabenstetter, Sahar Jalali, Andrea M Gazzo, Higinio Dopeso, Antonio Marra, David N Brown, Dara S Ross, Diana Mandelker und 8 weitere

Modern Pathology · 2024

DOI: 10.1016/j.modpat.2023.100375 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2024. Verfasst von Fatemeh Derakhshan und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Pathology and Cell Biology…. Hauptthemen laut MEDLINE: Carcinoma, Lobular, Breast Neoplasms, Carcinoma, Ductal, Breast. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CDH1 encodes for E-cadherin, and its loss of function is the hallmark of invasive lobular carcinoma (ILC). Albeit vanishingly rare, biallelic CDH1 alterations may be found in nonlobular breast carcinomas (NL-BCs). We sought to determine the clinicopathologic characteristics and repertoire of genetic alterations of NL-BCs harboring CDH1 biallelic genetic alterations. Analysis of 5842 breast cancers (BCs) subjected to clinical tumor-normal sequencing with an FDA-cleared multigene panel was conducted to identify BCs with biallelic CDH1 pathogenic/likely pathogenic somatic mutations lacking lobular features. The genomic profiles of NL-BCs with CDH1 biallelic genetic alterations were compared with those of ILCs and invasive ductal carcinomas (IDCs), matched by clinicopathologic characteristics. Of the 896 CDH1-altered BCs, 889 samples were excluded based on the diagnosis of invasive mixed ductal/lobular carcinoma or ILC or the detection of monoallelic CDH1 alterations. Only 7 of the 5842 (0.11%) BCs harbored biallelic CDH1 alterations and lacked lobular features. Of these, 4/7 (57%) cases were ER-positive/HER2-negative, 1/7 (14%) was ER-positive/HER2-positive, and 2/7 (29%) were ER-negative/HER2-negative. In total, 5/7 (71%) were of Nottingham grade 2, and 2/7 (29%) were of grade 3. The NL-BCs with CDH1 biallelic genetic alterations included a mucinous carcinoma (n = 1), IDCs with focal nested growth (n = 2), IDC with solid papillary (n = 1) or apocrine (n = 2) features, and an IDC of no special type (NST; n = 1). E-cadherin expression, as detected by immunohistochemistry, was absent (3/5) or aberrant (discontinuous membranous/cytoplasmic/granular; 2/5). However, NL-BCs with CDH1 biallelic genetic alterations displayed recurrent genetic alterations, including TP53, PIK3CA (57%, 4/7; each), FGFR1, and NCOR1 (28%, 2/7, each) alterations. Compared with CDH1 wild-type IDC-NSTs, NL-BCs less frequently harbored GATA3 mutations (0% vs 47%, P = .03), but no significant differences were detected when compared with matched ILCs. Therefore, NL-BCs with CDH1 biallelic genetic alterations are vanishingly rare, predominantly comprise IDCs with special histologic features, and have genomic features akin to luminal B ER-positive BCs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, LobularBreast NeoplasmsCarcinoma, Ductal, BreastHumansFemaleCadherinsGenomicsAntigens, CD

Stichwörter der Autor:innen

CDH1E-cadherinbreast cancerductallobular

Substanzen

CadherinsCDH1 protein, humanAntigens, CD

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, N…
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: parejaf@mskcc.org.
  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; AstraZeneca, Gaithersburg, Maryland.

Förderung

  • NCI NIH HHS

Zitieren

APA

Derakhshan, F., Da Cruz Paula, A., Selenica, P., da Silva, E. M., Grabenstetter, A., Jalali, S., Gazzo, A. M., Dopeso, H., Marra, A., Brown, D. N., Ross, D. S., Mandelker, D., Razavi, P., Chandarlapaty, S., Wen, H. Y., Brogi, E., Zhang, H., Weigelt, B., Pareja, F., & Reis-Filho, J. S. (2024). Nonlobular Invasive Breast Carcinomas with Biallelic Pathogenic CDH1 Somatic Alterations: A Histologic, Immunophenotypic, and Genomic Characterization. Modern Pathology. https://doi.org/10.1016/j.modpat.2023.100375

Vancouver

Derakhshan F, Da Cruz Paula A, Selenica P, da Silva EM, Grabenstetter A, Jalali S, et al. Nonlobular Invasive Breast Carcinomas with Biallelic Pathogenic CDH1 Somatic Alterations: A Histologic, Immunophenotypic, and Genomic Characterization. Modern Pathology. 2024. doi:10.1016/j.modpat.2023.100375

BibTeX
@article{Derakhshan2024,
  author = {Derakhshan, Fatemeh and Da Cruz Paula, Arnaud and Selenica, Pier and da Silva, Edaise M and Grabenstetter, Anne and Jalali, Sahar and Gazzo, Andrea M and Dopeso, Higinio and Marra, Antonio and Brown, David N and Ross, Dara S and Mandelker, Diana and Razavi, Pedram and Chandarlapaty, Sarat and Wen, Hannah Y and Brogi, Edi and Zhang, Hong and Weigelt, Britta and Pareja, Fresia and Reis-Filho, Jorge S},
  title = {Nonlobular Invasive Breast Carcinomas with Biallelic Pathogenic CDH1 Somatic Alterations: A Histologic, Immunophenotypic, and Genomic Characterization},
  journal = {Modern Pathology},
  year = {2024},
  doi = {10.1016/j.modpat.2023.100375}
}
Kostenlos starten →